You are here: Home » Current Affairs » Coronavirus » News
Business Standard

J&J confirms pausing Covid-19 vaccine trial because of unexplained illness

Earlier this month, Johnson & Johnson joined the short list of vaccine makers that have moved an experimental coronavirus shot into late-stage human studies

Topics
Coronavirus Vaccine | Coronavirus Tests | Coronavirus

Jeff Sutherland & Riley Griffin | Bloomberg 

JOHNSON & JOHNSON
J&J has since begun dosing up to 60,000 volunteers, marking the first big trial of an Covid-19 inoculation. (bloomberg)

said its Covid-19 vaccine study has been temporarily halted due to an unexplained illness in a trial participant.

Jake Sargent, a spokesman for the New Brunswick, New Jersey company, confirmed an earlier report by health-care news provider STAT that the study was paused.

Earlier this month, joined the short list of vaccine makers that have moved an experimental shot into late-stage human studies in the U.S. The company has since begun dosing up to 60,000 volunteers, marking the first big trial of an Covid-19 inoculation that may work after just one shot.

News of the halt comes after AstraZeneca Plc temporarily stopped tests of its vaccine after a trial participant fell ill. That study has resumed in a number of countries but remains halted in the U.S.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 13 2020. 07:17 IST
RECOMMENDED FOR YOU